NEW YORK, April 19  - Rosetta Inpharmatics reported $4.7 million in revenues for the first quarter of 2001 Thursday, up from $548,000 for the first quarter of 2000, while losses were narrower than Wall Street's expectations.

The Kirkland, Wash., bioinformatics company attributed the revenue surge to a collaboration with Monsanto in crop gene expression that the companies initiated at the end of November 2000, and to sales of the Rosetta Resolver system. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.